This is a surgical biospecimen collection study. The purpose of this study is to understand how much of two drugs (dabrafenib and trametinib) are able to penetrate brain tumors and turn off the RAF signaling pathway. This is important because these drugs are currently FDA approved for other tumors and may have efficacy in brain tumors with the BRAF V600E mutation.
Name: Surgical Cohort
Description: Obtain single time-point concentration of dabrafenib in enhancing brain tissue (ng/mL) using liquid chromatography/mass spectrometry with one single, random sample
Measure: Concentration of dabrafenib in brain tumor Time: Day 1Description: Obtain single time-point concentration of trametinib in enhancing brain tissue (ng/mL) using liquid chromatography/mass spectrometry with one single, random sample
Measure: Concentration of trametinib in brain tumor Time: Day 1Case-Only
There are 4 SNPs
Allowable mutations include V600E, V600K, V600R, and V600D. --- V600E --- --- V600K --- --- V600R --- --- V600D ---
A Biospecimen Collection Study to Evaluate the Pharmacokinetic, Pharmacodynamic, and Resistance Profile to Trametinib and Dabrafenib in BRAF-V600E Mutated Recurrent Gliomas. --- V600E ---
A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas This is a surgical biospecimen collection study. --- V600E ---
This is important because these drugs are currently FDA approved for other tumors and may have efficacy in brain tumors with the BRAF V600E mutation. --- V600E ---
Allowable mutations include V600E, V600K, V600R, and V600D. --- V600E ---
Glioma BRAF V600E Pleomorphic Xantho-Astrocytoma Glioblastoma Glioblastoma Glioma Astrocytoma The primary goal of this study is to establish concentrations of dabrafenib and trametinib in enhancing brain tissue and cerebrospinal fluid from people with BRAF-V600E mutant recurrent gliomas who undergo tumor resection. --- V600E ---
Glioma BRAF V600E Pleomorphic Xantho-Astrocytoma Glioblastoma Glioblastoma Glioma Astrocytoma The primary goal of this study is to establish concentrations of dabrafenib and trametinib in enhancing brain tissue and cerebrospinal fluid from people with BRAF-V600E mutant recurrent gliomas who undergo tumor resection. --- V600E --- --- V600E ---
Allowable mutations include V600E, V600K, V600R, and V600D. --- V600E --- --- V600K ---
Allowable mutations include V600E, V600K, V600R, and V600D. --- V600E --- --- V600K --- --- V600R ---